<Page>

                                                                    Exhibit 10.5

                                                                [EXECUTION COPY]

                             UNIT PURCHASE AGREEMENT

     THIS UNIT PURCHASE AGREEMENT (this "AGREEMENT") is made as of February 6,
2004, by and among Medtech/Denorex, LLC, a Delaware limited liability company
(the "COMPANY"), GTCR Fund VIII, L.P., a Delaware limited partnership ("GTCR
FUND VIII"), GTCR Fund VIII/B, L.P., a Delaware limited partnership ("GTCR FUND
VIII/B"), GTCR Co-Invest II, L.P., a Delaware limited partnership ("GTCR
CO-INVEST" and together with GTCR Fund VIII, GTCR Fund VIII/B and any investment
fund managed by GTCR Golder Rauner II, L.L.C. or GTCR Golder Rauner, L.L.C. that
at any time executes a counterpart of this Agreement or otherwise agrees to be
bound by this Agreement, the "GTCR PURCHASERS") and the TCW/Crescent Purchasers
(as defined herein). The GTCR Purchasers and the TCW/Crescent Purchasers are
collectively referred to herein as the "PURCHASERS" and each individually as a
"PURCHASER". Except as otherwise indicated herein, capitalized terms used herein
are defined in SECTION 6 hereof.

     The parties hereto agree as follows:

     Section 1.   AUTHORIZATION AND CLOSING.

             A.   AUTHORIZATION OF THE SECURITIES. The Company shall authorize
the issuance and sale to the Purchasers of up to 245,000 of its Class B
Preferred Units (the "CLASS B PREFERRED UNITS"), and up to 50,000,000 of its
Common Units (the "COMMON UNITS"), each having the rights and preferences set
forth in EXHIBIT B attached hereto. The Class B Preferred Units and the Common
Units are collectively referred to herein as the "SECURITIES."

             B.   PURCHASE AND SALE OF THE SECURITIES.

                  (a)    At the Initial Closing (as defined below), the Company
shall sell to the GTCR Purchasers and, subject to the terms and conditions set
forth herein, the GTCR Purchasers shall purchase from the Company, an aggregate
of 48,574,428 Common Units at a price of $0.10 per unit and an aggregate of
97,363.508 Class B Preferred Units at a price of $1,000 per unit. Each GTCR
Purchaser shall purchase the percentage of such Securities set forth next to
such GTCR Purchaser's name on the signature page attached hereto by payment of
the aggregate purchase price thereof by wire transfer of immediately available
funds to such account as is designated by the Company. In exchange therefor,
each GTCR Purchaser shall receive from the Company the certificate(s)
representing the Securities purchased by such GTCR Purchaser.

                  (b)    At the Initial Closing (as defined below), the Company
shall sell to the TCW/Crescent Purchasers and, subject to the terms and
conditions set forth herein, the TCW/Crescent Purchasers shall purchase from the
Company, an aggregate of 1,425,572 Common Units at a price of $0.10 per unit and
an aggregate of 2,857.443 Class B Preferred Units at a price of $1,000 per unit.
Each TCW/Crescent Purchaser shall purchase such Securities by payment of the
aggregate purchase price thereof by wire transfer of immediately available funds
to such account as is designated by the Company. In exchange therefor, each
TCW/Crescent Purchaser shall receive from the Company the certificate(s)
representing the

                                        1
<Page>

Securities purchased by such TCW/Crescent Purchaser. Notwithstanding anything to
the contrary herein, the aggregate amount of Securities which the TCW/Crescent
Purchasers are collectively purchasing hereunder shall be allocated among the
TCW/Crescent Purchasers in accordance with the allocation percentage opposite
each TCW/Crescent Purchaser's name under the heading "TCW/Crescent Purchaser
Allocations" on the "Schedule of TCW/Crescent Allocations" attached hereto.

                  (c)    The initial closing of the purchase and sale of the
Common Units and Class B Preferred Units (the "INITIAL CLOSING") shall take
place at the offices of Kirkland & Ellis LLP, 200 E. Randolph Drive, Chicago,
Illinois at 10:00 a.m. on the date hereof.

                  (d)    The Company has been organized for the purpose of
owning a company or companies in the consumer products industry. In addition to
the $102,220,951 invested by the GTCR Purchasers on the Initial Closing Date
pursuant to SECTION 1.B(a) above, the GTCR Purchasers intend to provide up to
$144,779,049 in equity financing to the Company as the equity portion of the
debt and equity financing necessary to fund such business(es), in each case as
approved by the Board of Managers of the Company (the "BOARD") and the GTCR
Purchasers (an "APPROVED USE"). The GTCR Purchasers' obligation to purchase any
Securities pursuant to this SECTION 1.B will be conditioned on the Company's not
being in default under any of its material agreements, adequate debt financing
being available to fund any proposed acquisition or other Approved Use on terms
satisfactory to the GTCR Purchasers, and the Company's operations and the
acquisition or other Approved Use being satisfactory to the GTCR Purchasers. In
order to implement the foregoing, the GTCR Purchasers may purchase from time to
time after the Initial Closing, upon the written request of the Board in
connection with an Approved Use, up to an aggregate of 144,779.049 Class B
Preferred Units at a price of $1,000 per unit (as adjusted from time to time as
a result of unit dividends, unit splits, recapitalizations and similar events)
(each such purchase, a "SUBSEQUENT CLOSING"). For any Subsequent Closing, each
GTCR Purchaser shall purchase the percentage of such Securities set forth next
to such GTCR Purchaser's name on the signature page attached hereto by payment
of the aggregate purchase price thereof by wire transfer of immediately
available funds to such account as is designated by the Company. In exchange
therefor, each GTCR Purchaser shall receive from the Company the certificate(s)
representing the Securities purchased by such GTCR Purchaser. Each Subsequent
Closing shall take place at the offices of Kirkland & Ellis LLP, 200 E. Randolph
Drive, Chicago, Illinois at 10:00 a.m. on such date as may be mutually agreeable
to the Company and the GTCR Purchasers. At the time of any Subsequent Closing,
the GTCR Purchasers shall be entitled to receive, and the Company shall be
obligated to deliver, satisfactory representations and warranties and all other
information and documentation as the GTCR Purchasers may reasonably request.

                  (e)    TCW/CRESCENT SUBSEQUENT CLOSINGS.

                  (i)    In connection with each Subsequent Closing, the
TCW/Crescent Purchasers may, but shall not be obligated to, purchase a number of
Class B Preferred Units equal to the total number of Class B Preferred Units
being purchased at such Subsequent Closing multiplied by .02851 and on the same
terms and conditions as the GTCR Purchasers; provided that if the TCW/Crescent
Purchasers choose not to purchase all of the Class B Preferred Units

                                        2
<Page>

they are entitled to purchase at any Subsequent Closing, they may not purchase
Class B Preferred Units at such Subsequent Closing or at any Subsequent Closing
thereafter.

                  (ii)   In connection with any Subsequent Closing in which the
TCW/Crescent Purchasers do not purchase shares of Class B Preferred Units, the
GTCR Purchasers shall have the right to purchase from the TCW/Crescent
Purchasers and transferees a number of Common Units. The number of Common Units
to be purchased hereunder will be determined by calculating the amount that the
TCW/Crescent Purchasers would have been entitled to invest had the TCW/Crescent
Purchasers participated in such Subsequent Closing and dividing that amount by
$7,127,858 (i.e., the TCW/Crescent Purchasers' total committed equity) (the
"Ratio"). The Ratio will then be multiplied by the number of Common Units held
by the TCW/Crescent Purchasers and its transferees immediately prior to such
Subsequent Closing. Such product will then be adjusted to give effect to any
change in the Fair Market Value of the Company and its Subsidiaries between the
date hereof and the date immediately preceding such Subsequent Closing before
giving effect to such Subsequent Closing by dividing such product by the
multiple of such increase in Fair Market Value of the Company and its
Subsidiaries or by 1 minus the percentage decrease in such Fair Market Value of
the Company and its Subsidiaries, as the case may be. Such right to purchase in
favor of the GTCR Purchasers (i) must be exercised on the date of the Subsequent
Closing if the TCW/Crescent Purchasers (or their transferees, as the case may
be) have notified the GTCR Purchasers at least three (3) Business Days prior to
such Subsequent Closing that they do not intend to participate in such
Subsequent Closing or otherwise within five (5) Business Days after such Closing
and (ii) shall not, under any circumstances, permit the GTCR Purchasers to
purchase any Common Units held by TCW/Crescent Purchasers or their transferees
as a result of the exercise of the TCW Warrants (as defined in that certain
Warrant Agreement dated as of the date hereof by and among the Company, GTCR
Capital Partners, L.P. and the TCW/Crescent Lenders (as defined therein)). "Fair
Market Value" for purposes of this Section 1.B(e) shall be the fair market value
of all equity of the Company using the methodology procedures set forth in the
definition of Fair Market Value in Section 6 hereof.

                  (iii)  The purchase price for each Common Unit repurchased
pursuant to this Section 1.B(e) will be $0.10 per unit (each as proportionately
adjusted for all subsequent unit splits, unit dividends and other
recapitalizations).

                  (iv)   The closing of the purchase of the Common Units
pursuant to the this Section 1.B(e) shall take place on the date designated in a
notice given to the TCW/Crescent Purchasers in accordance herewith, which date
shall not be more than 30 days nor less than five days after the delivery of
such notice. Each GTCR Purchaser will pay for the Common Units to be purchased
by it by a check or wire transfer of immediately available funds. The GTCR
Purchasers will be entitled to receive customary representations and warranties
from the sellers regarding such sale and to require that all sellers' signatures
be guaranteed.

     Section 2.   CONDITIONS OF THE PURCHASERS' OBLIGATION AT THE INITIAL
CLOSING AND EACH SUBSEQUENT CLOSING. The obligation of each Purchaser to
purchase and pay for the Securities to be purchased by it at the Initial Closing
is subject to the satisfaction as of the Initial Closing of the following
conditions (other than SECTION 2.Q) and the obligation of each Purchaser to

                                        3
<Page>

purchase and pay for the Securities to be purchased by it at each Subsequent
Closing is subject to the satisfaction as of such Subsequent Closing of the
conditions set forth in SECTION 2.Q:

             A.   REPRESENTATIONS AND WARRANTIES; COVENANTS. The representations
and warranties contained in SECTION 5 hereof shall be true and correct at and as
of the Initial Closing as though then made, except to the extent of changes
caused by the transactions expressly contemplated herein, and the Company shall
have performed in all material respects all of the covenants required to be
performed by it hereunder prior to the Initial Closing.

             B.   CERTIFICATE OF FORMATION. The Company's certificate of
formation (the "CERTIFICATE OF FORMATION") shall include the provisions set
forth in EXHIBIT A attached hereto, shall be in full force and effect under the
laws of Delaware as of the Initial Closing and shall not have been amended or
modified.

             C.   LIMITED LIABILITY COMPANY AGREEMENT. The Company and the
members of the Company shall have entered into an Amended and Restated Limited
Liability Company Agreement in form and substance substantially similar to
EXHIBIT B attached hereto (the "LLC AGREEMENT"), and the LLC Agreement shall be
in full force and effect as of the Initial Closing.

             D.   SENIOR MANAGEMENT AGREEMENTS. The Company and, as appropriate,
one or more of its Subsidiaries shall have entered into a Senior Management
Agreement (each, an "INITIAL SENIOR MANAGEMENT AGREEMENT"), in form and
substance substantially similar to EXHIBIT C attached hereto, with each of Peter
C. Mann, Peter Anderson, Mike Fink and Gerard F. Butler (each, an "EXECUTIVE"
and collectively, the "EXECUTIVES"). The Initial Senior Management Agreements
shall not have been amended or modified and shall be in full force and effect as
of the Initial Closing, and each Executive shall have purchased the Securities
proposed to be purchased by him thereunder.

             E.   SECURITYHOLDERS AGREEMENT. The Company, the Purchasers and the
Executives shall have entered into a securityholders agreement in form and
substance substantially similar to EXHIBIT D attached hereto (the
"SECURITYHOLDERS AGREEMENT"), and the Securityholders Agreement shall be in full
force and effect as of the Initial Closing.

             F.   REGISTRATION AGREEMENT. The Company, the Purchasers and the
Executives shall have entered into a registration agreement in form and
substance substantially similar to EXHIBIT E attached hereto (the "REGISTRATION
AGREEMENT"), and the Registration Agreement shall be in full force and effect as
of the Initial Closing.

             G.   PROFESSIONAL SERVICES AGREEMENT. A Subsidiary of the Company
and GTCR Golder Rauner II, L.L.C., a Delaware limited liability company ("GTCR
LLC") shall have entered into a professional services agreement in form and
substance substantially similar to EXHIBIT F attached hereto (the "PROFESSIONAL
SERVICES AGREEMENT"), and the Professional Services Agreement shall be in full
force and effect as of the Initial Closing.

             H.   MANAGEMENT SERVICES AGREEMENT. Certain Subsidiaries of the
Company shall have entered into a management services agreement in form and
substance substantially similar to EXHIBIT G attached hereto (the "MANAGEMENT
SERVICES AGREEMENT"), and the Management Services Agreement shall be in full
force and effect as of the Initial Closing.

                                        4
<Page>

             I.   STOCK PURCHASE AGREEMENT. Each of the conditions precedent to
the obligations of Medtech Acquisition and Denorex Acquisition under the Stock
Purchase Agreement shall have been satisfied or waived on or prior to the
Initial Closing.

             J.   SUBSIDIARY CHARTERS. Medtech Holdings, Denorex Holdings,
Management Company, Medtech Acquisition and Denorex Acquisition shall each have
duly adopted, executed and filed with the Secretary of State of Delaware a
certificate of incorporation in form and substance substantially similar to
EXHIBITS H, I, J, K AND L attached hereto, respectively (together, the
"CHARTERS"), and the Charters shall continue to be in full force and effect as
of the Initial Closing and shall not have been further amended or modified.

             K.   SUBSIDIARY BYLAWS. Medtech Holdings, Denorex Holdings,
Management Company, Medtech Acquisition and Denorex Acquisition shall each have
duly adopted bylaws in form and substance substantially similar to EXHIBITS M,
N, O, P AND Q attached hereto, respectively (together, the "BYLAWS"), and the
Bylaws shall continue to be in full force and effect as of the Initial Closing
and shall not have been further amended or modified.

             L.   DEBT FINANCING. Medtech Acquisition and Denorex Acquisition
shall have received senior debt and subordinated debt financing in the aggregate
face amount of $143,135,000 on terms and conditions satisfactory to Medtech
Acquisition and Denorex Acquisition.

             M.   INITIAL CLOSING DOCUMENTS. The Company shall have delivered to
the Purchasers all of the following documents:

                  (a)    an Officer's Certificate, dated the date of the Initial
Closing, stating that the conditions specified in SECTION 1 and SECTION 2.A
through 2L, inclusive, have been fully satisfied;

                  (b)    certified copies of the resolutions duly adopted by the
Board authorizing the execution, delivery and performance of this Agreement, the
LLC Agreement, the Initial Senior Management Agreements, the Securityholders
Agreement, the Registration Agreement, and each of the other agreements
contemplated hereby (the "TRANSACTION DOCUMENTS"), the issuance and sale of the
Securities and the consummation of all other transactions contemplated by this
Agreement;

                  (c)    certified copies of the resolutions duly adopted by the
shareholders of Medtech Holdings, Denorex Holdings and Management Company
adopting the Charter and the Bylaws; and

                  (d)    certified copies of the Company's Certificate of
Formation and the LLC Agreement, each as in effect at the Initial Closing.

             N.   FEES AND EXPENSES. The Company shall have reimbursed each
Purchaser for its fees and expenses as provided in SECTION 7.A hereof.

             O.   COMPLIANCE WITH APPLICABLE LAWS. The purchase of Securities by
the Purchasers hereunder shall not be prohibited by any applicable law or
governmental regulation,

                                        5
<Page>

shall not subject the Purchaser to any penalty, liability or, in each
Purchaser's sole judgment, other onerous conditions under or pursuant to any
applicable law or governmental regulation, and shall be permitted by laws and
regulations of the jurisdictions to which any Purchaser is subject.

             P.   CONSENTS AND APPROVALS. The Company shall have received or
obtained all governmental, regulatory and third party consents and approvals
necessary for the consummation of the transactions contemplated by the Initial
Closing.

             Q.   CONDITIONS TO SUBSEQUENT CLOSINGS. The obligation of each
Purchaser to purchase and pay for the Securities at any Subsequent Closing is
subject to the satisfaction as of the Subsequent Closing of the following
conditions:

                  (a)    REPRESENTATIONS AND WARRANTIES; COVENANTS. The
representations and warranties contained in SECTION 5 hereof shall be true and
correct at and as of such Subsequent Closing as though then made, except to the
extent of changes caused by the transactions expressly contemplated herein or by
the other Transaction Documents and except for changes occurring in the ordinary
course of the Company's and its Subsidiaries' businesses that have not had a
material adverse effect on the financial condition, operating results, assets,
operations or business prospects of the Company or any Subsidiary (including the
filing of any material litigation against the Company or any Subsidiary or the
existence of any material dispute with any Person that involves a reasonable
likelihood of such litigation being commenced). The Company shall have performed
in all material respects all of the covenants and agreements required to be
performed by it under this Agreement prior to such Subsequent Closing.

                  (b)    CONSENTS AND APPROVALS. The Company shall have received
or obtained all governmental, regulatory and third party consents and approvals
necessary for the consummation of the transactions contemplated by such
Subsequent Closing.

                  (c)    COMPLIANCE WITH APPLICABLE LAWS. The purchase of
Securities by the Purchasers hereunder shall not be prohibited by any applicable
law or governmental regulation, shall not subject the Purchaser to any penalty,
liability or, in each Purchaser's sole judgment, other onerous conditions under
or pursuant to any applicable law or governmental regulation, and shall be
permitted by laws and regulations of the jurisdictions to which any Purchaser is
subject.

             R.   WAIVER. Any condition specified in this SECTION 2 may be
waived only if such waiver is set forth in a writing executed by the GTCR
Purchasers.

     Section 3.   COVENANTS.

             A.   FINANCIAL STATEMENTS AND OTHER INFORMATION. The Company shall
deliver to each Purchaser (so long as such Purchaser holds any Securities) and
to each holder of at least 15% of the Investor Preferred and to each holder of
at least 15% of the Investor Common:

                  (a)    as soon as available but in any event within 30 days
after the end of each monthly accounting period in each fiscal year, unaudited
consolidating and consolidated

                                        6
<Page>

statements of income and cash flows of the Company and its Subsidiaries for such
monthly period and for the period from the beginning of the fiscal year to the
end of such month, and consolidating and consolidated balance sheets of the
Company and its Subsidiaries as of the end of such monthly period, all prepared
in accordance with United States generally accepted accounting principles,
consistently applied, subject to the absence of footnote disclosures and to
normal year-end adjustments;

                  (b)    accompanying the financial statements referred to in
subsection (a) above, an Officer's Certificate stating that neither the Company
nor any of its Subsidiaries is in default under any of its material agreements
or, if any such default exists, specifying the nature and period of existence
thereof and what actions the Company and its Subsidiaries have taken and propose
to take with respect thereto;

                  (c)    within 90 days after the end of each fiscal year,
consolidating and consolidated statements of income and cash flows of the
Company and its Subsidiaries for such fiscal year, and consolidating and
consolidated balance sheets of the Company and its Subsidiaries as of the end of
such fiscal year, setting forth in each case comparisons to the annual budget
and to the preceding fiscal year, all prepared in accordance with United States
generally accepted accounting principles, consistently applied, and accompanied
by (a) with respect to the consolidated portions of such statements (except with
respect to budget data), an opinion containing no exceptions or qualifications
(except for qualifications regarding specified contingent liabilities) of an
independent accounting firm of recognized national standing acceptable to the
Majority Holders, (b) a copy of such accounting firm's annual management letter
to the Board, and (c) an Officer's Certificate from either the chief executive
officer or chief financial officer of the Company stating the following: "To the
knowledge of the undersigned, the information contained in the financial
statements attached to this certificate fairly presents, in all material
respects, the financial condition and results of operations of the Company and
its Subsidiaries.";

                  (d)    promptly upon receipt thereof, any additional reports,
management letters or other detailed information concerning significant aspects
of the Company's operations or financial affairs given to the Company by its
independent accountants (and not otherwise contained in other materials provided
hereunder);

                  (e)    at least 30 days prior to the beginning of each fiscal
year, an annual budget prepared on a monthly basis for the Company and its
Subsidiaries for such fiscal year (displaying anticipated statements of income
and cash flows), and promptly upon preparation thereof any other significant
budgets prepared by the Company and any revisions of such annual or other
budgets, and within 30 days after any monthly period in which there is a
material adverse deviation from the annual budget, an Officer's Certificate
explaining the deviation and what actions the Company has taken and proposes to
take with respect thereto;

                  (f)    promptly (but in any event within five business days)
after:

                  (i)    the discovery or receipt of notice of any default under
any agreement to which the Company or any of its Subsidiaries is a party that is
reasonably likely to have a Material Adverse Effect;

                                        7
<Page>

                  (ii)   any litigation, action, investigation or proceeding is
commenced, or to the knowledge of the Company or any Subsidiary, is threatened
to be, or has a reasonable likelihood of being (based on the existence of any
material dispute with any Person or otherwise), commenced and that is, or any
pending litigation, action, investigation or proceeding that becomes, reasonably
likely to (A) have a material adverse effect on the ability of the Company or
any Subsidiary to perform its material obligations under its agreements, (B)
have a Material Adverse Effect or (C) constitute or result in a material breach
of any representation, warranty, covenant or agreement set forth in any
agreements;

                  (iii)  any material casualty, damage, destruction, loss or
forfeiture (whether or not covered by insurance and whether or not in the
ordinary course of business or consistent with past practice) having a Material
Adverse Effect;

                  (iv)   any material change in the conduct of the business of
the Company or any Subsidiary, or any material change in the manner in which the
Company or any Subsidiary markets, produces, distributes or sells its products
and services which has had or may reasonably be expected to have a Material
Adverse Effect;

                  (v)    any material change in any accounting procedures,
practices or the basis of accounting of the Company or any Subsidiary; or

                  (vi)   any other transaction, event or circumstance affecting
the Company or any Subsidiary reasonably likely to have a Material Adverse
Effect (including any material alteration or change in the business plan or
strategy of the Company or any Subsidiary);

an Officer's Certificate specifying the nature and period of existence thereof
and what actions the Company and its Subsidiaries have taken and propose to take
with respect thereto, and, to the extent applicable, until such matter(s) are
finally resolved, subsequent Officer's Certificates shall be delivered at the
end of every 90-day period beginning after the initial Officer's Certificate is
required to be delivered under this SECTION 3A(f) specifying the current status
of such matter(s); for purposes of this SECTION 3A(f), "MATERIAL ADVERSE EFFECT"
shall mean a material adverse effect on the business, liabilities, operations,
properties, assets, operating results, prospects or condition (financial or
otherwise) of the Company or any Subsidiary;

                  (g)    within 10 days after transmission thereof, copies of
all financial statements, proxy statements, reports and any other general
written communications that the Company sends to its equityholders and copies of
all registration statements and all regular, special or periodic reports that it
files, or any of its officers or directors file with respect to the Company,
with the Securities and Exchange Commission or with any securities exchange on
which any of the Company's securities are then listed, and copies of all press
releases and other statements made available generally by the Company to the
public concerning material developments in the Company's and its Subsidiaries'
businesses; and

                  (h)    with reasonable promptness, such other information and
financial data concerning the Company and its Subsidiaries as any Person
entitled to receive information under this SECTION 3.A may reasonably request.

                                        8
<Page>

Each of the financial statements referred to in subsections (a) and (c) shall be
true and correct in all material respects as of the dates and for the periods
stated therein, subject in the case of the unaudited financial statements to
changes resulting from normal year-end audit adjustments (none of which would,
alone or in the aggregate, be materially adverse to the financial condition,
operating results, assets, operations or business prospects of the Company and
its Subsidiaries taken as a whole).

             B.   MANAGEMENT RIGHTS. The Company shall permit any
representatives designated by any Purchaser (so long as such Purchaser holds any
Securities) or any holder of at least 15% of the Investor Preferred or at least
15% of the Investor Common, upon reasonable notice and during normal business
hours and such other times as any such holder may reasonably request, to (a)
visit and inspect any of the properties of the Company and its Subsidiaries, (b)
examine the corporate and financial records of the Company and its Subsidiaries
and make copies thereof or extracts therefrom and (c) discuss the affairs,
finances and accounts of any such entities with the directors, officers, key
employees and independent accountants of the Company and its Subsidiaries;
provided that the Company shall have the right to have its chief financial
officer present at any meetings with the independent accountants of the Company.

             C.   RESTRICTIONS.  The Company shall not, without the prior
written consent of the Majority Holders:

                  (a)    directly or indirectly declare or pay any dividends or
make any distributions upon any of its equity securities, other than
distributions of unpaid yield or unreturned capital on the Class A Preferred
Units or the Class B Preferred Units pursuant to the LLC Agreement;

                  (b)    directly or indirectly redeem, purchase or otherwise
acquire, or permit any Subsidiary to redeem, purchase or otherwise acquire, any
of the Company's equity securities (including, without limitation, warrants,
options and other rights to acquire equity securities);

                  (c)    except as expressly contemplated by this Agreement or
the Senior Management Agreements, authorize, issue, sell or enter into any
agreement providing for the issuance (contingent or otherwise), or permit any
Subsidiary to authorize, issue, sell or enter into any agreement providing for
the issuance (contingent or otherwise) of, (i) any notes or debt securities
containing equity features (including, without limitation, any notes or debt
securities convertible into or exchangeable for equity securities, issued in
connection with the issuance of equity securities or containing profit
participation features) or (ii) any equity securities (or any securities
convertible into or exchangeable for any equity securities) or rights to acquire
any equity securities, other than the issuance of equity securities by a
Subsidiary to the Company or another Subsidiary;

                  (d)    make, or permit any Subsidiary to make, any loans or
advances to, guarantees for the benefit of, or Investments in, any Person,
except for (A) reasonable advances to employees in the ordinary course of
business as well as travel advances, (B) relocation loans, (C) trade credit
extended to customers in the ordinary course of business and (D) Investments
having a stated maturity no greater than one year from the date the Company
makes such

                                        9
<Page>

Investment in (1) obligations of the United States government or any agency
thereof or obligations guaranteed by the United States government, (2)
certificates of deposit of commercial banks having combined capital and surplus
of at least $50 million, (3) commercial paper with a rating of at least
"Prime-1" by Moody's Investors Service, Inc. or (4) money market accounts
investing in any of the foregoing or in substantially similar investments;

                  (e)    merge or consolidate with any Person or permit any
Subsidiary to merge or consolidate with any Person (other than a wholly-owned
Subsidiary);

                  (f)    sell, lease or otherwise dispose of, or permit any
Subsidiary to sell, lease or otherwise dispose of, more than 5% of the
consolidated assets of the Company and its Subsidiaries (computed on the basis
of book value, determined in accordance with United States generally accepted
accounting principles consistently applied, or fair market value, determined by
the Board in its reasonable good faith judgment) in any transaction or series of
related transactions (other than sales of inventory in the ordinary course of
business);

                  (g)    except as contemplated by the LLC Agreement and the
Securityholders Agreement in connection with a Public Offering or Reorganization
(as defined in the Securityholders Agreement), liquidate, dissolve or effect a
recapitalization or reorganization in any form of transaction (including,
without limitation, any reorganization into a corporation or a partnership);

                  (h)    acquire, or permit any Subsidiary to acquire, any
interest in any business (whether by a purchase of assets, purchase of
securities, merger or otherwise), or enter into any joint venture;

                  (i)    enter into the ownership, active management or
operation of any business other than the ownership of the securities of its
Subsidiaries or permit any Subsidiary to enter into the ownership, active
management or operation of any business other than a business in the consumer
products industry;

                  (j)    enter into, or permit any Subsidiary to enter into, any
agreement, contractual commitment or other transaction (including, without
limitation, relating to any of the properties, assets or businesses of the
Company or any Subsidiary or the acquisition or disposition of property, rights
or assets (including, without limitation, any leasehold estate) of the Company
or any Subsidiary) with any of its or any Subsidiary's officers, directors,
nominees for election as a director, employees, equityholders or Affiliates or
any individual related by blood, marriage or adoption to any such Person (a
"RELATIVE") or any entity in which any such Person or individual owns a
beneficial interest (a "RELATED ENTITY"), except for normal employment
arrangements and benefit programs on reasonable terms and except as otherwise
expressly contemplated by this Agreement, the Senior Management Agreements and
the Professional Services Agreement;

                  (k)    become subject to, or permit any of its Subsidiaries to
become subject to, any agreement or instrument that by its terms would (under
any circumstances) restrict (A) the right of any Subsidiary to make loans or
advances or pay dividends to, transfer property to, or repay any Indebtedness
owed to, the Company or any Subsidiary or (B) the

                                       10
<Page>

Company's right to perform the provisions of this Agreement, the Certificate of
Formation, the LLC Agreement or the other Transaction Documents;

                  (l)    except as expressly contemplated by this Agreement,
make any amendment to the Certificate of Formation or the LLC Agreement that
would increase the number of authorized Securities or adversely affect or
otherwise impair the rights or the relative preferences and priorities of the
holders of the Securities under this Agreement, the Certificate of Formation,
the LLC Agreement or the other Transaction Documents;

                  (m)    create, incur, assume or suffer to exist, or permit any
Subsidiary to create, incur, assume or suffer to exist, Indebtedness exceeding
the amounts approved therefor by the Board in the annual budget; or

                  (n)    directly or indirectly (through one or more of its
Subsidiaries) waive any conditions precedent to the obligations of Medtech
Acquisition or Denorex Acquisition under the Stock Purchase Agreement.

             D.   AFFIRMATIVE COVENANTS. So long as the  Purchasers  hold any
Securities, the Company shall, and shall cause each Subsidiary to:

                  (a)    comply with all applicable laws, rules and regulations
of all governmental authorities, the violation of which would reasonably be
expected to have a material adverse effect upon the financial condition,
operating results, assets, operations or business prospects of the Company and
its Subsidiaries taken as a whole, and pay and discharge when payable all taxes,
assessments and governmental charges (except to the extent the same are being
contested in good faith and adequate reserves therefor have been established);
and

                  (b)    enter into and maintain appropriate nondisclosure and
noncompete agreements with its key employees.

             E.   CURRENT PUBLIC INFORMATION. At all times after the Company (or
its successor) has filed a registration statement with the Securities and
Exchange Commission pursuant to the requirements of either the Securities Act or
the Securities Exchange Act, the Company (or its successor) shall file all
reports required to be filed by it under the Securities Act and the Securities
Exchange Act and the rules and regulations adopted by the Securities and
Exchange Commission thereunder and shall take such further action as any holder
or holders of Restricted Securities may reasonably request, all to the extent
required to enable such holders to sell Restricted Securities pursuant to (a)
Rule 144 adopted by the Securities and Exchange Commission under the Securities
Act (as such rule may be amended from time to time) or any similar rule or
regulation hereafter adopted by the Securities and Exchange Commission or (b) a
registration statement on Form S-2 or S-3 or any similar registration form
hereafter adopted by the Securities and Exchange Commission. Upon request, the
Company (or its successor) shall deliver to any holder of Restricted Securities
a written statement as to whether it has complied with such requirements.

             F.   AMENDMENT OF OTHER AGREEMENTS. The Company shall not amend,
modify or waive any provision of the Senior Management Agreements or any other
agreement with key executives of the Company without the prior written consent
of the Majority Holders.

                                       11
<Page>

The Company shall enforce the provisions of the Senior Management Agreements and
any other agreement with key executives of the Company and shall exercise all of
its rights and remedies thereunder (including, without limitation, any
repurchase options and first refusal rights) unless it is otherwise directed by
the Majority Holders.

             G.   PUBLIC DISCLOSURES. The Company shall not, nor shall it permit
any Subsidiary to, disclose any Purchaser's or any of its Affiliates' name or
identity as an investor in the Company in any press release or other public
announcement or in any document or material filed with any governmental entity,
without the prior written consent of such Purchaser, unless such disclosure is
required by applicable law or governmental regulations or by order of a court of
competent jurisdiction, in which case prior to making such disclosure the
Company shall give written notice to such Purchaser describing in reasonable
detail the proposed content of such disclosure and shall permit such Purchaser
to review and comment upon the form and substance of such disclosure.

             H.   UNRELATED BUSINESS TAXABLE INCOME; EFFECTIVELY CONNECTED
INCOME. The Company shall not engage in any transaction which is reasonably
likely to cause any Purchaser or any limited partner thereof that is exempt from
income taxation under Section 501(a) of the IRC and, if applicable, any pension
plan that any such trust may be a part of, to recognize unrelated business
taxable income as defined in Section 512 and Section 514 of the IRC. The Company
will use reasonable best efforts not to engage in, or invest in any Person that
is treated as a flow-through entity for U.S. federal income tax purposes that
engages in, (a) any "commercial activity" as defined in Section 892(a)(2)(i) of
the IRC or (b) transactions which will cause the Company to incur income that is
effectively connected with a "trade or business within the United States" as
defined in Section 864(b) of the IRC.

             I.   HART-SCOTT-RODINO COMPLIANCE. In connection with any
transaction in which the Company is involved (a "TRANSACTION") that is required
to be reported under the Hart-Scott-Rodino Antitrust Improvements Act of 1976,
as amended from time to time (the "HSR ACT"), the Company shall prepare and file
all documents with the Federal Trade Commission and the United States Department
of Justice which may be required to comply with the HSR Act, and shall promptly
furnish all materials thereafter requested by any of the regulatory agencies
having jurisdiction over such filings, in connection with a Transaction. The
Company shall take all reasonable actions and shall file and use reasonable best
efforts to have declared effective or approved all documents and notifications
with any governmental or regulatory bodies, as may be necessary or may
reasonably be requested under federal antitrust laws for the consummation of the
Transaction. Notwithstanding the foregoing, if any Purchaser, rather than the
Company, is required to make a filing under the HSR Act in connection with a
Transaction, the Company will provide to such Purchaser all necessary
information for such filing, will facilitate such filing and will pay all fees
and expenses associated with such filing.

             J.   ADDITIONAL ACCOUNTING PROCEDURES. Upon the request of the GTCR
Purchasers, the Company and its Subsidiaries will cause its accounting firm to
conduct additional procedures with respect to, and monitor and evaluate, the
Company's and any Subsidiary's executive compensation, expense reimbursement and
related-party transactions policies and practices.

                                       12
<Page>

     Section 4.   TRANSFER OF RESTRICTED SECURITIES.

                  (a)    Restricted Securities are transferable only pursuant to
(i) Public Offerings, (ii) Rule 144 of the Securities and Exchange Commission
(or any similar rule or rules then in force) if such rule or rules are available
and (iii) subject to the conditions specified in clause (b) below, any other
legally available means of transfer.

                  (b)    In connection with the transfer of any Restricted
Securities (other than a transfer described in SECTION 4(a)(i) or (ii) above or
a transfer to an Affiliate of a Purchaser), the holder thereof shall deliver
written notice to the Company describing in reasonable detail the transfer or
proposed transfer, together with an opinion of Kirkland & Ellis LLP, Gardere
Wynne Sewell LLP or other counsel that (to the Company's reasonable
satisfaction) is knowledgeable in securities law matters to the effect that such
transfer of Restricted Securities may be effected without registration of such
Restricted Securities under the Securities Act. In addition, if the holder of
the Restricted Securities delivers to the Company an opinion of Kirkland & Ellis
LLP or such other counsel that no subsequent transfer of such Restricted
Securities shall require registration under the Securities Act, the Company
shall promptly upon such contemplated transfer deliver to the prospective
transferor new certificates for such Restricted Securities that do not bear the
Securities Act legend set forth in SECTION 7.C. If the Company is not required
to deliver new certificates for such Restricted Securities not bearing such
legend, the holder thereof shall not transfer the same until the prospective
transferee has confirmed to the Company in writing its agreement to be bound by
the conditions contained in this SECTION 4 and SECTION 7.C.

                  (c)    Upon the request of a Purchaser, the Company shall
promptly supply to such Purchaser or its prospective transferees all information
regarding the Company required to be delivered in connection with a transfer
pursuant to Rule 144A of the Securities and Exchange Commission.

     Section 5.   REPRESENTATIONS AND WARRANTIES OF THE COMPANY. As a material
inducement to each Purchaser to enter into this Agreement and purchase the
Securities, the Company hereby represents and warrants to each Purchaser that:

             A.   ORGANIZATION AND CORPORATE POWER. The Company is a limited
liability company duly organized, validly existing and in good standing under
the laws of Delaware and is qualified to do business in every jurisdiction in
which the failure to so qualify might reasonably be expected to have a material
adverse effect on the financial condition, operating results, assets, operations
or business prospects of the Company and its Subsidiaries taken as a whole. The
Company has all requisite limited liability company power and authority and all
material licenses, permits and authorizations necessary to own and operate its
properties, to carry on its businesses as now conducted and presently proposed
to be conducted and to carry out the transactions contemplated by this
Agreement. The copies of the Company's Certificate of Formation and the LLC
Agreement that have been furnished to the Purchasers reflect all amendments made
thereto at any time prior to the date of this Agreement and are correct and
complete.

                                       13
<Page>

             B.   EQUITY SECURITIES AND RELATED MATTERS.

                  (a)    As of the Initial Closing and immediately thereafter,
the authorized equity securities of the Company shall consist of the following:
(i) an unlimited number of units designated as Class A Preferred Units, none of
which shall be issued and outstanding and all of which may only be issued in
exchange for other equity securities of the Company pursuant to the terms of the
Senior Management Agreements; (ii) an unlimited number of units designated as
Class B Preferred Units, 106,656.438 of which shall be issued and outstanding,
144,779.049 of which shall be reserved for issuance to the Purchasers pursuant
to SECTION 1.B hereof and none of which shall be reserved for issuance upon
exercise of options and warrants granted by the Company; and (iii) an unlimited
number of units designated as Common Units, 55,282,269 of which shall be issued
and outstanding, none of which shall be reserved for issuance to the Purchasers
pursuant to SECTION 1.B hereof and 2,619,386 of which shall be reserved for
issuance upon exercise of options and warrants granted by the Company and
881,751 of which will be reserved for issuance to employee of the Company and
its Subsidiaries. As of the Initial Closing, the Company shall not be subject to
any obligation (contingent or otherwise) to repurchase or otherwise acquire or
retire any of its equity securities or any warrants, options or other rights to
acquire its equity securities, except pursuant to this Agreement, the LLC
Agreement, the Senior Management Agreements and the Company's Certificate of
Formation. As of the Initial Closing, all of the Company's outstanding equity
securities shall be validly issued, fully paid and nonassessable.

                  (b)    There are no statutory or, to the best of the Company's
knowledge, contractual securityholders preemptive rights or rights of refusal
with respect to the issuance of the Securities hereunder or the issuance of the
Securities pursuant to SECTION 1.B(d), except as expressly contemplated in the
Securityholders Agreement, the LLC Agreement or as provided herein. Based in
part on the investment representations of the Purchasers in SECTION 7.C hereof
and of Executives in Section 1(f) of the Senior Management Agreements, the
Company has not violated any applicable federal or state securities laws in
connection with the offer, sale or issuance of any of its equity securities, and
the offer, sale and issuance of the Securities hereunder and pursuant to SECTION
1.B(d) hereof do not and will not require registration under the Securities Act
or any applicable state securities laws. To the best of the Company's knowledge,
there are no agreements between the Company's securityholders with respect to
the voting or transfer of the Company's equity securities or with respect to any
other aspect of the Company's affairs, except for the Securityholders Agreement,
the LLC Agreement, the Senior Management Agreements, the Registration Agreement
and the Professional Services Agreement.

             C.   SUBSIDIARIES; INVESTMENTS. Immediately after the consummation
of the Initial Closing, the entities set forth on SCHEDULE 4C will be the
Company's only Subsidiaries. Immediately after the consummation of the Initial
Closing, the Company will own 100% of the capital stock of Medtech Holdings,
Denorex Holdings and Management Company. Each of the Subsidiaries set forth on
SCHEDULE 4C is validly existing and in good standing under the laws of the state
of its incorporation, possesses all requisite corporate power and authority and
all material licenses, permits and authorizations necessary to own its
properties and to carry on its business as now being conducted and as presently
proposed to be conducted and is qualified to do business in every jurisdiction
in which its ownership of property or the conduct of its business requires it to
qualify.

                                       14
<Page>

             D.   AUTHORIZATION; NO BREACH. The execution, delivery and
performance of this Agreement, the LLC Agreement, the Senior Management
Agreements, the Securityholders Agreement, the Registration Agreement and all
other agreements contemplated hereby to which the Company is a party have been
duly authorized by the Company. This Agreement, the Senior Management
Agreements, the Securityholders Agreement, the Registration Agreement, the
Certificate of Formation and all other agreements contemplated hereby each
constitutes a valid and binding obligation of the Company, enforceable in
accordance with its terms. The execution and delivery by the Company of this
Agreement, the LLC Agreement, the Senior Management Agreements, the
Securityholders Agreement, the Registration Agreement and all other agreements
contemplated hereby to which the Company is a party, the offering, sale and
issuance of the Securities hereunder (including pursuant to SECTION 1.B(d)) and
the fulfillment of and compliance with the respective terms hereof and thereof
by the Company do not and will not (i) conflict with or result in a breach of
the terms, conditions or provisions of, (ii) constitute a default under, (iii)
result in the creation of any lien, security interest, charge or encumbrance
upon the Company's equity securities or assets pursuant to, (iv) give any third
party the right to modify, terminate or accelerate any obligation under, (v)
result in a violation of, or (vi) require any authorization, consent, approval,
exemption or other action by or notice to any court or administrative or
governmental body pursuant to, the Certificate of Formation of the Company or
the LLC Agreement, or any law, statute, rule or regulation to which the Company
is subject, or any agreement, instrument, order, judgment or decree to which the
Company is a party or by which it is bound.

             E.   CONDUCT OF BUSINESS; LIABILITIES. Other than in connection
with the negotiation, execution and delivery of this Agreement, the Senior
Management Agreements, the Securityholders Agreement, the Registration
Agreement, the Professional Services Agreement, the Management Services
Agreement and the other agreements contemplated hereby and thereby and the
consummation of the transactions set forth in the Stock Purchase Agreement
(including the financing contemplated thereunder), prior to the Initial Closing,
the Company has not (i) conducted any business, (ii) incurred any expenses,
obligations or liabilities (whether accrued, absolute, contingent, unliquidated
or otherwise, whether or not known to the Company and whether due or to become
due and regardless of when asserted), (iii) owned any assets, (iv) entered into
any contracts or agreements, or (v) violated any laws or governmental rules or
regulations.

             F.   LITIGATION, ETC. There are no actions, suits, proceedings,
orders, investigations or claims pending or, to the best of the Company's
knowledge, threatened against or affecting either the Company or the Company's
Subsidiaries (or to the best of the Company's knowledge, pending or threatened
against or affecting any of the officers, directors or employees of the Company
or Medtech Holdings, Denorex Holdings and Management Company with respect to
their businesses or proposed business activities) at law or in equity, or before
or by any governmental department, commission, board, bureau, agency or
instrumentality with respect to the transactions contemplated by this Agreement.

             G.   BROKERAGE. There are no claims for brokerage commissions,
finders' fees or similar compensation in connection with the transactions
contemplated by this Agreement based on any arrangement or agreement binding
upon the Company. The Company shall pay,

                                       15
<Page>

and hold the Purchasers harmless against, any liability, loss or expense
(including, without limitation, attorneys' fees and out-of-pocket expenses)
arising in connection with any such claim.

             H.   GOVERNMENTAL CONSENT, ETC. No permit, consent, approval or
authorization of, or declaration to or filing with, any governmental authority
is required in connection with the execution, delivery and performance by the
Company of this Agreement or the other agreements contemplated hereby, or the
consummation by the Company of any other transactions contemplated hereby or
thereby.

             I.   DISCLOSURE. Neither this Agreement nor any of the schedules,
attachments, written statements, documents, certificates or other items prepared
or supplied to the Purchasers by or on behalf of the Company with respect to the
transactions contemplated hereby contain any untrue statement of a material fact
or omit a material fact necessary to make each statement contained herein or
therein not misleading. There is no fact which the Company has not disclosed to
the Purchasers in writing and of which any of its officers, directors, managers
or executive employees is aware and which has had or might reasonably be
anticipated to have a material adverse effect upon the existing or expected
financial condition, operating results, assets, customer or supplier relations,
employee relations or business prospects of the Company.

             J.   INITIAL CLOSING DATE. The representations and warranties of
the Company contained in this SECTION 5 and elsewhere in this Agreement and all
information contained in any exhibit, schedule or attachment hereto or in any
writing delivered by, or on behalf of, the Company to the Purchasers shall be
true and correct in all material respects on the date of the Initial Closing as
though then made, except as affected by the transactions expressly contemplated
by this Agreement.

     Section 6.   DEFINITIONS.  For the purposes of this Agreement, the
following terms have the meanings set forth below:

     "AFFILIATE" of any particular Person or entity means any other person or
entity controlling, controlled by or under common control with such particular
person or entity. For purposes of this Agreement, all holdings of Class B
Preferred Units and Common Units by Persons who are Affiliates of each other
shall be aggregated for purposes of meeting any threshold tests under this
Agreement.

     "CLASS A PREFERRED UNITS" means the Class A Preferred Units, as defined in
the LLC Agreement.

     "COMMON UNITS" means the Common Units, as defined in the LLC Agreement.

     "DENOREX ACQUISITION" means Denorex Acquisition, Inc., a Delaware
corporation.

     "DENOREX HOLDINGS" means Denorex Acquisition Holdings, Inc., a Delaware
corporation.

     "FAIR MARKET VALUE" of each Common Unit means the average of the closing
prices of the sales of such Common Units on all securities exchanges on which
such Common Units may at the time be listed, or, if there have been no sales on
any such exchange on any day, the average of the highest bid and lowest asked
prices on all such exchanges at the end of such day, or, if on

                                       16
<Page>

any day such Common Units are not so listed, the average of the representative
bid and asked prices quoted in the NASDAQ System as of 4:00 P.M., New York time,
or, if on any day such Common Units are not quoted in the NASDAQ System, the
average of the highest bid and lowest asked prices on such day in the domestic
over-the-counter market as reported by the National Quotation Bureau
Incorporated, or any similar successor organization, in each such case averaged
over a period of 21 days consisting of the day as of which the Fair Market Value
is being determined and the 20 consecutive business days prior to such day. If
at any time such Common Units are not listed on any securities exchange or
quoted in the NASDAQ System or the over-the-counter market, the Fair Market
Value will be the fair value of such Common Units as determined in good faith by
the Board (the "BOARD CALCULATION"). If the holders of a majority of the Common
Units subject to a Securities Repurchase reasonably disagree with such
determination, such holders shall deliver to the Board a written notice of
objection (an "OBJECTION") within ten days after delivery of the Board
Calculation. Upon receipt of an Objection, the Board and such holders will
negotiate in good faith to agree on such Fair Market Value. If such agreement is
not reached within 20 days after the delivery of the Objection, Fair Market
Value shall be determined by an appraiser jointly selected by the Board and such
holders, which appraiser shall submit to the Board and such holders a report
within 30 days of its engagement setting forth such determination. If the
parties are unable to agree on an appraiser within 25 days after delivery of the
Objection, within seven days, each of the Board and such holders shall submit
the names of four nationally recognized firms that are engaged in the business
of valuing non-public securities, and each of the Board and such holders shall
be entitled to strike two names from the other party's list of firms, and the
appraiser shall be selected by lot from the remaining four investment banking
firms. The expenses of such appraiser shall be borne by the holders, pro rata
among them, unless the appraiser's valuation is more than 10% greater than the
Board Calculation, in which case the expenses of the appraiser shall be borne by
the Company. The determination of such appraiser as to Fair Market Value shall
be final and binding upon all parties.

     "INDEBTEDNESS" means all indebtedness for borrowed money (including
purchase money obligations) maturing one year or more from the date of creation
or incurrence thereof or renewable or extendible at the option of the debtor to
a date one year or more from the date of creation or incurrence thereof, all
indebtedness under revolving credit arrangements extending over a year or more,
all capitalized lease obligations and all guarantees of any of the foregoing.

     "INVESTOR COMMON" means (i) any Common Units issued pursuant to this
Agreement and (ii) any Common Units issued or issuable with respect to the
Common Units referred to in clause (i) above by way of unit dividends or unit
splits or in connection with a combination of units, recapitalization, merger,
consolidation or other reorganization. As to any particular units of Investor
Common, such units shall cease to be Investor Common when they have been (a)
effectively registered under the Securities Act and disposed of in accordance
with the registration statement covering them or (b) distributed to the public
through a broker, dealer or market maker pursuant to Rule 144 under the
Securities Act (or any similar rule then in force).

     "INVESTOR PREFERRED" means (i) the Class B Preferred Units issued hereunder
(including, without limitation, pursuant to SECTION 1.B(d)), and (ii) any Class
B Preferred Units issued or issuable with respect to the Class B Preferred Units
referred to in clause (i) above by way of unit dividends or unit splits or in
connection with a combination of units, recapitalization, merger,

                                       17
<Page>

consolidation or other reorganization. As to any particular units of Investor
Preferred, such units shall cease to be Investor Preferred when they have been
(a) effectively registered under the Securities Act and disposed of in
accordance with the registration statement covering them or (b) distributed to
the public through a broker, dealer or market maker pursuant to Rule 144 under
the Securities Act (or any similar rule then in force).

     "INVESTOR SECURITIES" means, collectively, the Investor Preferred and the
Investor Common.

     "INVESTMENT" as applied to any Person means (i) any direct or indirect
purchase or other acquisition by such Person of any notes, obligations,
instruments, stock, securities or ownership interest (including partnership
interests and joint venture interests) of any other Person and (ii) any capital
contribution by such Person to any other Person.

     "IRC" means the Internal Revenue Code of 1986, as amended, and any
reference to any particular IRC Section shall be interpreted to include any
revision of or successor to that Section regardless of how numbered or
classified.

     "MAJORITY HOLDERS" means the holders of a majority of the Investor
Preferred or, if no Investor Preferred is outstanding, the holders of a majority
of the Investor Common.

     "MANAGEMENT COMPANY" means Medtech/Denorex Management, Inc., a Delaware
corporation.

     "MEDTECH ACQUISITION" means Medtech Acquisition, Inc., a Delaware
corporation.

     "MEDTECH HOLDINGS" means Medtech Acquisition Holdings, Inc., a Delaware
corporation.

     "OFFICER'S CERTIFICATE" means a certificate signed by the Company's chief
executive officer or its chief financial officer, stating that (i) the officer
signing such certificate has made or has caused to be made such investigations
as are necessary in order to permit such officer to verify the accuracy of the
information set forth in such certificate and (ii) to the best of such officer's
knowledge, such certificate does not misstate any material fact and does not
omit to state any fact necessary to make the certificate not misleading.

     "PERSON" means an individual, a partnership, a limited liability company, a
corporation, an association, a joint stock company, a trust, a joint venture, an
unincorporated organization, an investment fund, any other business entity and a
governmental entity or any department, agency or political subdivision thereof.

     "PUBLIC OFFERING" means the sale in a public offering registered under the
Securities Act of equity securities of the Company or a corporate successor to
the Company.

     "RESTRICTED SECURITIES" means (i) the Securities issued hereunder and
pursuant to SECTION 1.B(d) hereof and (ii) any securities issued with respect to
the securities referred to in clause (i) above by way of a unit dividend or unit
split or in connection with a combination of units, recapitalization, merger,
consolidation or other reorganization. As to any particular Restricted
Securities, such securities shall cease to be Restricted Securities when they
have (a) been

                                       18
<Page>

effectively registered under the Securities Act and disposed of in accordance
with the registration statement covering them, (b) become eligible for sale
pursuant to Rule 144(k) (or any similar provision then in force) under the
Securities Act or (c) been otherwise transferred and new certificates for them
not bearing the Securities Act legend set forth in SECTION 7.C have been
delivered by the Company in accordance with SECTION 4(b). Whenever any
particular securities cease to be Restricted Securities, the holder thereof
shall be entitled to receive from the Company, without expense, new securities
of like tenor not bearing a Securities Act legend of the character set forth in
SECTION 7.C.

     "SECURITIES ACT" means the Securities Act of 1933, as amended, or any
similar federal law then in force.

     "SECURITIES EXCHANGE ACT" means the Securities Exchange Act of 1934, as
amended, or any similar federal law then in force.

     "SECURITIES AND EXCHANGE COMMISSION" includes any governmental body or
agency succeeding to the functions thereof.

     "SENIOR MANAGEMENT AGREEMENT" means any Senior Management Agreement entered
into from time to time among the Company, Management Company (or any other
Subsidiaries of the Company) and its executives, as the same may be amended from
time to time pursuant to the terms thereof.

     "STOCK PURCHASE AGREEMENT" means the Stock Purchase Agreement dated as of
January 7, 2004, by and among Medtech Holdings, Inc., each stockholder of
Medtech Holdings, Inc. listed on SCHEDULE 3.1 thereto, The Denorex Company, each
stockholder of The Denorex Company listed on SCHEDULE 3.1 thereto, Medtech
Acquisition and Denorex Acquisition.

     "SUBSIDIARY" means, with respect to any Person, any corporation, limited
liability company, partnership, association, or business entity of which (i) if
a corporation, a majority of the total voting power of shares of stock entitled
(without regard to the occurrence of any contingency) to vote in the election of
directors, managers, or trustees thereof is at the time owned or controlled,
directly or indirectly, by that Person or one or more of the other Subsidiaries
of that Person or a combination thereof, or (ii) if a limited liability company,
partnership, association, or other business entity (other than a corporation), a
majority of partnership or other similar ownership interest thereof is at the
time owned or controlled, directly or indirectly, by that Person or one or more
Subsidiaries of that Person or a combination thereof. For purposes hereof, a
Person or Persons shall be deemed to have a majority ownership interest in a
limited liability company, partnership, association, or other business entity
(other than a corporation) if such Person or Persons shall be allocated a
majority of limited liability company, partnership, association, or other
business entity gains or losses or shall be or control any managing director or
general partner of such limited liability company, partnership, association, or
other business entity. For purposes hereof, references to a "SUBSIDIARY" of any
Person shall be given effect only at such times that such Person has one or more
Subsidiaries, and, unless otherwise indicated, the term "Subsidiary" refers to a
Subsidiary of the Company.

                                       19
<Page>

     "TCW/CRESCENT PURCHASERS" means collectively, TCW/Crescent Mezzanine
Partners III, L.P., a Delaware limited partnership, TCW/Crescent Mezzanine Trust
III, a Delaware business trust, and TCW/Crescent Mezzanine Partners III
Netherlands, L.P., a Delaware limited partnership, any of their Affiliates or
any investment fund for whom Trust Company of the West or any Affiliate of Trust
Company of the West acts as an account manager.

     Section 7.   MISCELLANEOUS.

             A.   EXPENSES. The Company agrees to pay, and hold each Purchaser
and all holders of Investor Securities harmless against liability for the
payment of, (i) the reasonable fees and expenses of its counsel arising in
connection with the negotiation and execution of this Agreement and the
consummation of the transactions contemplated by this Agreement (including,
without limitation, fees and expenses arising with respect to any subsequent
purchase of Securities pursuant to SECTION 1.B(d) hereof), (ii) the fees and
expenses incurred with respect to any amendments or waivers (whether or not the
same become effective) under or in respect of this Agreement, the LLC Agreement,
the Senior Management Agreements, the Securityholders Agreement, the
Registration Agreement, the other agreements contemplated hereby and the
Certificate of Formation, (iii) stamp and other taxes that may be payable in
respect of the execution and delivery of this Agreement or the issuance,
delivery or acquisition of any Securities purchased hereunder or in accordance
with SECTION 1.B(d) hereof, (iv) the fees and expenses incurred with respect to
the interpretation or enforcement of the rights granted under this Agreement,
the LLC Agreement, the Senior Management Agreements, the Securityholders
Agreement, the Registration Agreement, the Professional Services Agreement, the
other agreements contemplated hereby and the Certificate of Formation and (v)
such reasonable travel expenses, legal fees and other out-of-pocket fees and
expenses as have been or may be incurred by any Purchaser, its Affiliates and
its Affiliates' directors, officers and employees in connection with any
Company-related financing and in connection with the rendering of any other
services by a Purchaser or its Affiliates (including, but not limited to, fees
and expenses incurred in attending board of managers or other Company-related
meetings).

             B.   REMEDIES. Each holder of Investor Securities shall have all
rights and remedies set forth in this Agreement, the LLC Agreement and the
Certificate of Formation and all rights and remedies that such holders have been
granted at any time under any other agreement or contract and all of the rights
that such holders have under any law. Any Person having any rights under any
provision of this Agreement shall be entitled to enforce such rights
specifically (without posting a bond or other security), to recover damages by
reason of any breach of any provision of this Agreement and to exercise all
other rights granted by law.

             C.   EACH PURCHASER'S INVESTMENT REPRESENTATIONS. Each Purchaser,
severally and not jointly, hereby represents (i) that it is acquiring the
Restricted Securities purchased hereunder or acquired pursuant hereto for its
own account with the present intention of holding such securities for purposes
of investment, and that it has no intention of selling such securities in a
public distribution in violation of the federal securities laws or any
applicable state securities laws, (ii) that it is an "accredited investor" and a
sophisticated investor for purposes of applicable U.S. federal and state
securities laws and regulations, (iii) that the Restricted Securities were not
offered to such Purchaser by any means of general solicitation or general
advertising, (iv) that it believes that it has such knowledge and experience in
financial and business matters that such

                                       20
<Page>

Purchaser is capable of evaluating the merits and risks of an investment in the
Company, (v) that it is able to bear the economic risks of an investment in the
Restricted Securities and could afford a complete loss of such investment, (vi)
that this Agreement and each of the other agreements contemplated hereby to
which such Purchaser is a party constitutes (or will constitute) the legal,
valid and binding obligation of such Purchaser, enforceable in accordance with
its terms and (vii) that the execution, delivery and performance of this
Agreement and such other agreements by such Purchaser does not and will not
conflict with, violate or cause a breach of any agreement, contract or
instrument to which such Purchaser is subject. Notwithstanding the foregoing,
nothing contained herein shall prevent any Purchaser and subsequent holders of
Restricted Securities from transferring such securities in compliance with the
provisions of SECTION 4 hereof. Each certificate for Restricted Securities shall
be imprinted with a legend in substantially the following form:

             "THE SECURITIES REPRESENTED BY THIS CERTIFICATE WERE
             ORIGINALLY ISSUED ON [DATE OF ISSUANCE] AND HAVE NOT BEEN
             REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
             THE TRANSFER OF THE SECURITIES REPRESENTED BY THIS
             CERTIFICATE IS SUBJECT TO THE CONDITIONS SPECIFIED IN THE
             UNIT PURCHASE AGREEMENT, DATED AS OF FEBRUARY 6, 2004 BY
             AND AMONG THE ISSUER (THE "COMPANY") AND CERTAIN
             INVESTORS, AND THE COMPANY RESERVES THE RIGHT TO REFUSE
             THE TRANSFER OF SUCH SECURITIES UNTIL SUCH CONDITIONS
             HAVE BEEN FULFILLED WITH RESPECT TO SUCH TRANSFER. A COPY
             OF SUCH CONDITIONS SHALL BE FURNISHED BY THE COMPANY TO
             THE HOLDER HEREOF UPON WRITTEN REQUEST AND WITHOUT
             CHARGE."

             D.   CONSENT TO AMENDMENTS. Except as otherwise expressly provided
herein, the provisions of this Agreement may be amended and the Company may take
any action herein prohibited, or omit to perform any act herein required to be
performed by it, only if the Company has obtained the written consent of the
Majority Holders. No other course of dealing between the Company and the holder
of any Securities or any delay in exercising any rights hereunder or under the
Certificate of Formation shall operate as a waiver of any rights of any such
holders. For purposes of this Agreement, Securities held by the Company or any
of its Subsidiaries shall not be deemed to be outstanding.

             E.   SURVIVAL OF REPRESENTATIONS AND WARRANTIES. All
representations and warranties contained herein or made in writing by any party
in connection herewith shall survive the execution and delivery of this
Agreement and the consummation of the transactions contemplated hereby,
regardless of any investigation made by a Purchaser or on its behalf.

             F.   SUCCESSORS AND ASSIGNS. Except as otherwise expressly provided
herein, all covenants and agreements contained in this Agreement by or on behalf
of any of the parties hereto shall bind and inure to the benefit of the
respective successors and assigns of the parties hereto whether so expressed or
not. In addition, and whether or not any express assignment has been made, the
provisions of this Agreement that are for each Purchaser's benefit as a
purchaser

                                       21
<Page>

or holder of Securities are also for the benefit of, and enforceable by, any
subsequent holder of such Securities. The rights and obligations of each
Purchaser under this Agreement and the agreements contemplated hereby may be
assigned by such Purchaser at any time, in whole or in part, to any investment
fund managed by GTCR LLC or GTCR Golder Rauner, L.L.C. or any successor thereto
or any Affiliate of the TCW/Crescent Purchasers.

             G.   GENERALLY ACCEPTED ACCOUNTING PRINCIPLES. Where any accounting
determination or calculation is required to be made under this Agreement or the
exhibits hereto, such determination or calculation (unless otherwise provided)
shall be made in accordance with United States generally accepted accounting
principles, consistently applied, except that if because of a change in United
States generally accepted accounting principles the Company would have to alter
a previously utilized accounting method or policy in order to remain in
compliance with United States generally accepted accounting principles, such
determination or calculation shall continue to be made in accordance with the
Company's previous accounting methods and policies.

             H.   SEVERABILITY. Whenever possible, each provision of this
Agreement shall be interpreted in such manner as to be effective and valid under
applicable law, but if any provision of this Agreement is held to be invalid,
illegal or unenforceable in any respect under any applicable law or rule in any
jurisdiction, such invalidity, illegality or unenforceability will not affect
any other provision or any other jurisdiction, but this Agreement will be
reformed, construed and enforced in such jurisdiction as if such invalid,
illegal or unenforceable provision had never been contained herein.

             I.   COUNTERPARTS. This Agreement may be executed simultaneously in
two or more counterparts, any one of which need not contain the signatures of
more than one party, but all such counterparts taken together shall constitute
one and the same Agreement.

             J.   DELIVERY BY FACSIMILE. This Agreement, the agreements referred
to herein, and each other agreement or instrument entered into in connection
herewith or therewith or contemplated hereby or thereby, and any amendments
hereto or thereto, to the extent signed and delivered by means of a facsimile
machine, shall be treated in all manner and respects as an original agreement or
instrument and shall be considered to have the same binding legal effect as if
it were the original signed version thereof delivered in person. At the request
of any party hereto or to any such agreement or instrument, each other party
hereto or thereto shall reexecute original forms thereof and deliver them to all
other parties. No party hereto or to any such agreement or instrument shall
raise the use of a facsimile machine to deliver a signature or the fact that any
signature or agreement or instrument was transmitted or communicated through the
use of a facsimile machine as a defense to the formation or enforceability of a
contract and each such party forever waives any such defense.

             K.   DESCRIPTIVE HEADINGS; INTERPRETATION. The descriptive headings
of this Agreement are inserted for convenience only and do not constitute a
section of this Agreement. The use of the word "including" in this Agreement
shall be by way of example rather than by limitation.

                                       22
<Page>

             L.   GOVERNING LAW. The Delaware Limited Liability Company Act
shall govern all issues concerning the relative rights of the Company and its
securityholders. All other questions concerning the construction, validity and
interpretation of this Agreement and the exhibits and schedules hereto shall be
governed by and construed in accordance with the internal laws of the State of
Delaware, without giving effect to any choice of law or conflict of law
provision or rule (whether of the State of Delaware or any other jurisdiction)
that would cause the application of the laws of any jurisdiction other than the
State of Delaware.

             M.   MUTUAL WAIVER OF JURY TRIAL. BECAUSE DISPUTES ARISING IN
CONNECTION WITH COMPLEX TRANSACTIONS ARE MOST QUICKLY AND ECONOMICALLY RESOLVED
BY AN EXPERIENCED AND EXPERT PERSON AND THE PARTIES WISH APPLICABLE STATE AND
FEDERAL LAWS TO APPLY (RATHER THAN ARBITRATION RULES), THE PARTIES DESIRE THAT
THEIR DISPUTES BE RESOLVED BY A JUDGE APPLYING SUCH APPLICABLE LAWS. THEREFORE,
TO ACHIEVE THE BEST COMBINATION OF THE BENEFITS OF THE JUDICIAL SYSTEM AND OF
ARBITRATION, EACH PARTY TO THIS AGREEMENT HEREBY WAIVES ALL RIGHTS TO TRIAL BY
JURY IN ANY ACTION, SUIT, OR PROCEEDING BROUGHT TO RESOLVE ANY DISPUTE BETWEEN
OR AMONG ANY OF THE PARTIES HERETO, WHETHER ARISING IN CONTRACT, TORT OR
OTHERWISE, ARISING OUT OF, CONNECTED WITH, RELATED OR INCIDENTAL TO THIS
AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

             N.   NOTICES. All notices, demands or other communications to be
given or delivered under or by reason of the provisions of this Agreement shall
be in writing and shall be deemed to have been given when (i) delivered
personally to the recipient, (ii) sent to the recipient by reputable express
courier service (charges prepaid), (iii) mailed to the recipient by certified or
registered mail, return receipt requested and postage prepaid, or (iv)
telecopied to the recipient (with hard copy sent to the recipient by reputable
overnight courier service (charges prepaid) that same day) if telecopied before
5:00 p.m. Chicago, Illinois time on a business day, and otherwise on the next
business day. Such notices, demands and other communications shall be sent to
the Purchasers at the address set forth on the PURCHASER NOTICE SCHEDULE
attached hereto and to the Company at the address indicated below:

             IF TO THE COMPANY:

                  Medtech/Denorex, LLC
                  90 North Broadway
                  Irvington, New York 10533
                  Attention:  Chief Executive Officer
                  Telephone: 914-524-6801
                  Facsimile: 914-524-6802

                  WITH COPIES TO:

                  GTCR Golder Rauner II, L.L.C.
                  6100 Sears Tower
                  Chicago, Illinois  60606-6402

                                       23
<Page>

                  Attention:  David A. Donnini and Vincent J. Hemmer
                  Telephone: (312) 382-2200
                  Facsimile: (312) 382-2201

                  Kirkland & Ellis LLP
                  200 East Randolph Drive
                  Chicago, Illinois  60601
                  Attention:  Stephen L. Ritchie, P.C.
                  Telephone: (312) 861-2000
                  Facsimile: (312) 861-2200


or to such other address or to the attention of such other person as the
recipient party has specified by prior written notice to the sending party.

             O.   ENTIRE AGREEMENT. This Agreement, those documents expressly
referred to herein and other documents of even date herewith embody the complete
agreement and understanding among the parties and supersede and preempt any
prior understandings, agreements or representations by or among the parties,
written or oral, that may have related to the subject matter hereof in any way.

             P.   UNDERSTANDING AMONG THE PURCHASERS. The determination of each
Purchaser to purchase the Securities pursuant to this Agreement has been made by
such Purchaser independent of any other Purchaser and independent of any
statements or opinions as to the advisability of such purchase or as to the
properties, business, prospects or condition (financial or otherwise) of the
Company which may have been made or given by any other Purchaser or by any agent
or employee of any other Purchaser. In addition, it is acknowledged by each of
the Purchasers that no Purchaser has acted as an agent of any other Purchaser in
connection with making its investment hereunder and that no Purchaser shall be
acting as an agent of any other Purchaser in connection with monitoring its
investment hereunder. It is further acknowledged by each of the other Purchasers
that the GTCR Purchasers have retained Kirkland & Ellis LLP to act as their
counsel in connection with the transactions contemplated hereby and that
Kirkland & Ellis LLP has not acted as counsel for any of the other Purchasers in
connection herewith and that none of the other Purchasers has the status of a
client of Kirkland & Ellis LLP for conflict of interest or other purposes as a
result thereof.

                                    * * * * *

                                       24
<Page>

     IN WITNESS WHEREOF, the parties hereto have executed this Unit Purchase
Agreement on the date first written above.

                                       MEDTECH/DENOREX, LLC


                                       By:  /S/ AARON S. COHEN
                                          ------------------------------------
                                       Name:    Aaron S. Cohen
                                            ----------------------------------
                                       Title:  Secretary
                                             ---------------------------------


PERCENTAGE:                            GTCR FUND VIII, L.P.

84.686%                                By:    GTCR Partners VIII, L.P.
                                       Its:   General Partner

                                       By:    GTCR Golder Rauner II, L.L.C.
                                       Its:   General Partner


                                       By:         /S/ DAVID A. DONNINI
                                              --------------------------------
                                       Name:  David A. Donnini
                                       Its:   Principal


PERCENTAGE:                            GTCR FUND VIII/B, L.P.

14.862%                                By:    GTCR Partners VIII, L.P.
                                       Its:   General Partner

                                       By:    GTCR Golder Rauner II, L.L.C.
                                       Its:   General Partner


                                       By:         /S/ DAVID A. DONNINI
                                              --------------------------------
                                       Name:  David A. Donnini
                                       Its:   Principal


        [Medtech/Denorex, LLC: Signature Page to Unit Purchase Agreement]

                                       25
<Page>

PERCENTAGE:                            GTCR CO-INVEST II, L.P.

0.452%                                 By:    GTCR Golder Rauner II, L.L.C.
                                       Its:   General Partner


                                       By:         /S/ DAVID A. DONNINI
                                              -------------------------------
                                       Name:  David A. Donnini
                                       Its:   Principal


                                       TCW/CRESCENT MEZZANINE PARTNERS III, L.P.
                                       TCW/CRESCENT MEZZANINE TRUST III
                                       TCW/CRESCENT MEZZANINE PARTNERS III
                                         NETHERLANDS, L.P.

                                       By:    TCW/Crescent Mezzanine
                                              Management III, L.L.C.,
                                              its Investment Manager

                                       By:    TCW Asset Management Company,
                                              its Sub-Advisor


                                       By:      /S/ TIMOTHY P. COSTELLO
                                              ------------------------------
                                       Name:     Timothy P. Costello
                                              -------------------------------
                                       Title:   Managing Director
                                              -------------------------------


        [Medtech/Denorex, LLC: Signature Page to Unit Purchase Agreement]

                                       26
<Page>

                                LIST OF EXHIBITS

Exhibit A    -    Certificate of Formation

Exhibit B    -    Form of Limited Liability Company Agreement

Exhibit C    -    Form of Senior Management Agreement

Exhibit D    -    Form of Securityholders Agreement

Exhibit E    -    Form of Registration Rights Agreement

Exhibit F    -    Form of Professional Services Agreement

Exhibit G    -    Form of Management Services Agreement

Exhibit H    -    Form of Medtech Acquisition Holdings, Inc. Certificate of
                  Incorporation

Exhibit I    -    Form of Denorex Acquisition Holdings, Inc. Certificate of
                  Incorporation

Exhibit J    -    Form of Medtech/Denorex Management, Inc. Certificate of
                  Incorporation

Exhibit K    -    Form of Medtech Acquisition, Inc. Certificate of Incorporation

Exhibit L    -    Form of Denorex Acquisition, Inc. Certificate of Incorporation

Exhibit M    -    Form of Medtech Acquisition Holdings, Inc. Bylaws

Exhibit N    -    Form of Denorex Acquisition Holdings, Inc. Bylaws

Exhibit O    -    Form of Medtech/Denorex Management, Inc. Bylaws

Exhibit P    -    Form of Medtech Acquisition, Inc. Bylaws

Exhibit Q    -    Form of Denorex Acquisition, Inc. Bylaws

<Page>

                                   SCHEDULE 4C

                          List of Company Subsidiaries

Medtech/Denorex Management, Inc.

Medtech Acquisition Holdings, Inc.

Denorex Acquisition Holdings, Inc.

Medtech Acquisition, Inc.

Denorex Acquisition, Inc.

Medtech Holdings, Inc.

The Denorex Company

Medtech Products, Inc.

Pecos Pharmaceutical, Inc.

The Cutex Company

<Page>

                            PURCHASE NOTICE SCHEDULE

IF TO THE GTCR PURCHASERS:

GTCR Fund VIII, L.P.
GTCR Fund VIII/B, L.P.
GTCR Co-Invest II, L.P.
c/o GTCR Golder Rauner II, L.L.C.
6100 Sears Tower
Chicago, IL  60606-6402
Attention:  David A. Donnini and Vincent J. Hemmer


WITH A COPY TO:

Kirkland & Ellis LLP
200 East Randolph Drive
Chicago, IL  60601
Attention:  Stephen L. Ritchie, P.C.

IF TO THE TCW/CRESCENT PURCHASERS:

TCW/Crescent Mezzanine Partners III, L.P.
TCW/Crescent Mezzanine Trust III
TCW/Crescent Mezzanine Partners III Netherlands, L.P.
c/o TCW/Crescent Mezzanine, L.L.C.
200 Crescent Court, Suite 1600
Dallas, Texas  75201
Attention:  Timothy P. Costello
Telecopier No.:  (214) 740-7382

WITH A COPY TO:

Gardere Wynne Sewell LLP
3000 Thanksgiving Tower
1601 Elm Street
Dallas, Texas  75201
Attention:  Gary B. Clark
Telecopier No.:  (214) 999-4667

<Page>

                      SCHEDULE OF TCW/CRESCENT ALLOCATIONS

<Table>
<Caption>
TCW/CRESCENT PURCHASER                                  TCW/CRESCENT PURCHASER ALLOCATIONS
-----------------------------------------------------   ----------------------------------
<S>                                                                               <C>
TCW/CRESCENT MEZZANINE PARTNERS III, L.P.                                         83.5667%

TCW/CRESCENT MEZZANINE TRUST III                                                  13.0190%

TCW/CRESCENT MEZZANINE PARTNERS III NETHERLANDS, L.P.                              3.4143%
</Table>